The legal action, spearheaded by the firm Robbins LLP, covers investors who acquired Regeneron stock between August 1, 2025, and May 15, 2026. According to the filing, the company allegedly obscured the fact that its treatment arm was failing to demonstrate meaningful clinical differentiation from standard therapies. Plaintiffs assert that the trial was unlikely to reach statistical significance on its primary endpoint, a reality they claim was hidden behind overly optimistic corporate messaging.

Market volatility followed the disclosure of these underlying trial issues. On April 29, 2026, Regeneron revealed it had altered the study parameters to expand patient eligibility for progression-free survival analysis. Shares fell 6.2% that day, dropping from $731.77 to $686.36. The decline deepened on May 15, 2026, when the company officially announced the trial failed to meet its primary endpoint. The stock price slipped an additional 9.8% by the following trading session, closing at $629.68 on May 18. Investors seeking to serve as lead plaintiff in the ongoing litigation are encouraged to contact Robbins LLP, which operates on a contingency fee basis.